Cargando…

Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus

BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in program...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkabab, Y., Warkentin, J., Cummins, J., Katz, B., Denison, B. M., Bartok, A., Khalil, A., Young, L. R., Timme, E., Peloquin, C. A., Ashkin, D., Houpt, E. R., Heysell, S. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904402/
https://www.ncbi.nlm.nih.gov/pubmed/36853114
http://dx.doi.org/10.5588/ijtld.22.0448
_version_ 1784883607439933440
author Alkabab, Y.
Warkentin, J.
Cummins, J.
Katz, B.
Denison, B. M.
Bartok, A.
Khalil, A.
Young, L. R.
Timme, E.
Peloquin, C. A.
Ashkin, D.
Houpt, E. R.
Heysell, S. K.
author_facet Alkabab, Y.
Warkentin, J.
Cummins, J.
Katz, B.
Denison, B. M.
Bartok, A.
Khalil, A.
Young, L. R.
Timme, E.
Peloquin, C. A.
Ashkin, D.
Houpt, E. R.
Heysell, S. K.
author_sort Alkabab, Y.
collection PubMed
description BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in programs with routine TDM vs. programs that did not use TDM, we conducted a retrospective study among people with DM and TB at health departments in four US states. RESULTS: A total of 170 patients were enrolled (73 patients in the non-TDM group and 97 patients in the TDM group). Days to sputum culture conversion and total treatment duration were significantly shorter in the TDM group vs. the non-TDM group. In adjusted analyses, patients who underwent TDM were significantly more likely to achieve sputum culture conversion at 2 months (P = 0.007). CONCLUSION: TDM hastened microbiological cure from TB among people with DM and a high risk for poor treatment outcomes in the programmatic setting.
format Online
Article
Text
id pubmed-9904402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher International Union Against Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-99044022023-02-09 Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus Alkabab, Y. Warkentin, J. Cummins, J. Katz, B. Denison, B. M. Bartok, A. Khalil, A. Young, L. R. Timme, E. Peloquin, C. A. Ashkin, D. Houpt, E. R. Heysell, S. K. Int J Tuberc Lung Dis Original Articles BACKGROUND: Diabetes mellitus (DM) increases the risk of TB disease and poor treatment outcomes such as delayed sputum culture conversion due to inadequate drug exposure. Therapeutic drug monitoring (TDM) has improved these outcomes in some settings. METHODS: To compare treatment outcomes in programs with routine TDM vs. programs that did not use TDM, we conducted a retrospective study among people with DM and TB at health departments in four US states. RESULTS: A total of 170 patients were enrolled (73 patients in the non-TDM group and 97 patients in the TDM group). Days to sputum culture conversion and total treatment duration were significantly shorter in the TDM group vs. the non-TDM group. In adjusted analyses, patients who underwent TDM were significantly more likely to achieve sputum culture conversion at 2 months (P = 0.007). CONCLUSION: TDM hastened microbiological cure from TB among people with DM and a high risk for poor treatment outcomes in the programmatic setting. International Union Against Tuberculosis and Lung Disease 2023-02 2023-02-01 /pmc/articles/PMC9904402/ /pubmed/36853114 http://dx.doi.org/10.5588/ijtld.22.0448 Text en © 2023 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Articles
Alkabab, Y.
Warkentin, J.
Cummins, J.
Katz, B.
Denison, B. M.
Bartok, A.
Khalil, A.
Young, L. R.
Timme, E.
Peloquin, C. A.
Ashkin, D.
Houpt, E. R.
Heysell, S. K.
Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title_full Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title_fullStr Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title_full_unstemmed Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title_short Therapeutic drug monitoring and TB treatment outcomes in patients with diabetes mellitus
title_sort therapeutic drug monitoring and tb treatment outcomes in patients with diabetes mellitus
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904402/
https://www.ncbi.nlm.nih.gov/pubmed/36853114
http://dx.doi.org/10.5588/ijtld.22.0448
work_keys_str_mv AT alkababy therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT warkentinj therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT cumminsj therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT katzb therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT denisonbm therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT bartoka therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT khalila therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT younglr therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT timmee therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT peloquinca therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT ashkind therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT houpter therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus
AT heysellsk therapeuticdrugmonitoringandtbtreatmentoutcomesinpatientswithdiabetesmellitus